StockMacro
Menu

BillionToOne

$89.92 +6.4% in 6 monthsMarket cap $4.3B

BLLN on XNAS, Health Care, BillionToOne, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue jumped 47% to $123M, but the stock fell 14% in the past month.

  • GoodTwelve-month revenue up 72% to $436.9M; net profit $49.4M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Industry
Services-medical laboratories (Health Care)
Employees
713
Website
billiontoone.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $123.0M, net income $17.4M.
Quarter to 30 Sep 2024: revenue $38.4M, net income -$14.9MQuarter to 30 Sep 2024: revenue $38.4M, net income -$14.9MQuarter to 31 Dec 2024: revenue $45.1M, net income -$11.5MQuarter to 31 Dec 2024: revenue $45.1M, net income -$11.5MQuarter to 31 Mar 2025: revenue $59.0M, net income -$4.0MQuarter to 31 Mar 2025: revenue $59.0M, net income -$4.0MQuarter to 30 Jun 2025: revenue $66.6M, net income -$246KQuarter to 30 Jun 2025: revenue $66.6M, net income -$246KQuarter to 30 Sep 2025: revenue $83.5M, net income $5.7MQuarter to 30 Sep 2025: revenue $83.5M, net income $5.7MQuarter to 31 Dec 2025: revenue $96.1M, net income $6.0MQuarter to 31 Dec 2025: revenue $96.1M, net income $6.0MQuarter to 31 Mar 2026: revenue $108.4M, net income $18.0MQuarter to 31 Mar 2026: revenue $108.4M, net income $18.0MQuarter to 30 Jun 2026: revenue $109.4M, net income $8.1MQuarter to 30 Jun 2026: revenue $109.4M, net income $8.1MQuarter to 30 Sep 2026: revenue $123.0M, net income $17.4MQuarter to 30 Sep 2026: revenue $123.0M, net income $17.4M
30 Sep 2024RevenueNet incomeNet losstallest bar $123.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$123.0M$17.4M
30 Jun 2026$109.4M$8.1M
31 Mar 2026$108.4M$18.0M
31 Dec 2025$96.1M$6.0M
30 Sep 2025$83.5M$5.7M
30 Jun 2025$66.6M-$246K
31 Mar 2025$59.0M-$4.0M
31 Dec 2024$45.1M-$11.5M
30 Sep 2024$38.4M-$14.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $436.9M $254.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +72% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $49.4M -$10.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.92 -$1.44
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 71.4% 65.2% 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 10.2% -2.4% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 11.3% -3.9% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $33.9M -$4.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $561.5M $195.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $89.0M $55.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$472.5M (net cash) -$140.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.16 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 87.0 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 9.8 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 8.8 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 7.6 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
BillionToOneBLLN (this company) $4.3B87.09.8+72%11.3%
GRAILGRAL $4.5Bloss26.8+17%-244%
CareDxCDNA $3.7B28.67.4+39%25.9%
Caris Life SciencesCAI $5.0B52.54.8+61%9.2%
RadNetRDNT $5.5Bloss2.3+21%-0.9%
CelcuityCELC $2.6Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$26.7M

bought $0, sold $26.7M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+7.7%

168 13F filers vs 156

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

3.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.7

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.3%

2.9M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 65%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

79

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+47%

$123.0M vs $83.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+86%

$3.9M vs $2.1M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.3×

25 articles in the last 7 days; its usual week has 3.

Price $89.92 on 20 Nov 2026, -6.0% over 12 months (12-month range $64.03 to $149.97)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $58.5M in the last 12 months (the 12 months before: $3.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 10 published in the last 12 months, +25% on the 12 months before.
Revenue per quarter. Revenue $123.0M in the latest quarter, +47% on a year earlier.
Capital spending per quarter. Capital spending $3.9M in the latest quarter, +86% on a year earlier.
Institutional holders (13F filers). 168 13F filers reported holding it in the latest 13F quarter, +98% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
4 Mar 20268-K and other filingsDirector or officer change
9 Dec 20258-K and other filingsDirector or officer change
9 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Nov 2025Sharp changeClustered insider buying: clustered insider buying (6 independent filers, 6 filing(s) in 30 days, value_usd total 3.2M)
17 Oct 20258-K and other filingsRegistered new securities for sale (S-1)
7 Oct 20258-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Nov 2025: $3.2M published
Month from 1 Jun 2026: -$9.2M published
Month from 1 Jul 2026: -$12.4M published
Month from 1 Aug 2026: -$11.3M published
Month from 1 Sep 2026: -$11.8M published
Month from 1 Oct 2026: -$8.0M published
Month from 1 Nov 2026: -$5.8M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Jul 2024: 6 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 8 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 30 Sep 2024: $38.4M; public on 11 Dec 2025
Quarter ended 31 Dec 2024: $45.1M; public on 12 Mar 2026
Quarter ended 31 Mar 2025: $59.0M; public on 7 May 2026
Quarter ended 30 Jun 2025: $66.6M; public on 6 Aug 2026
Quarter ended 30 Sep 2025: $83.5M, +117% on a year earlier; public on 11 Dec 2025
Quarter ended 31 Dec 2025: $96.1M, +113% on a year earlier; public on 12 Mar 2026
Quarter ended 31 Mar 2026: $108.4M, +84% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $109.4M, +64% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $123.0M, +47% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2024: $2.1M; public on 12 Mar 2026
Quarter ended 31 Mar 2025: $2.3M; public on 7 May 2026
Quarter ended 30 Jun 2025: $2.9M; public on 6 Aug 2026
Quarter ended 30 Sep 2025: $2.1M; public on 11 Dec 2025
Quarter ended 31 Dec 2025: $1.5M, -26% on a year earlier; public on 12 Mar 2026
Quarter ended 31 Mar 2026: $4.5M, +90% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $4.0M, +41% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $3.9M, +86% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2025 report: 85; public on 17 Feb 2026
31 Mar 2026 report: 88; public on 15 May 2026
30 Jun 2026 report: 156; public on 14 Aug 2026
30 Sep 2026 report: 168; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 168 (30 Sep 2026), 1.9× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $58.5M in the last 12 months (the 12 months before: $3.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 10 published in the last 12 months, +25% on the 12 months before.
  • Revenue per quarter: Revenue $123.0M in the latest quarter, +47% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 44 insider trades

Last 90 days: 19 sales, $26.7M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
4 Nov 2026Bosch John Roderick tenSVP of Laboratory OperationsSellplanned in advance (10b5-1)2,834$113.17$321KForm 4
4 Nov 2026Oguzhan AtayChairman and CEOSellplanned in advance (10b5-1); after exercising options30,335$109.93$3.3MForm 4
4 Nov 2026David TsaoChief Technology OfficerSellplanned in advance (10b5-1); after exercising options20,000$109.24$2.2MForm 4
30 Oct 2026Oguzhan AtayChairman and CEOSellplanned in advance (10b5-1); after exercising options11,000$118.00$1.3MForm 4
16 Oct 2026Oguzhan AtayChairman and CEOSellplanned in advance (10b5-1); after exercising options11,000$99.14$1.1MForm 4
14 Oct 2026Oguzhan AtayChairman and CEOSellplanned in advance (10b5-1); after exercising options19,334$94.31$1.8MForm 4
7 Oct 2026Bosch John Roderick tenSVP of Laboratory OperationsSellplanned in advance (10b5-1)2,834$105.15$298KForm 4
7 Oct 2026David TsaoChief Technology OfficerSellplanned in advance (10b5-1); after exercising options20,000$108.15$2.2MForm 4

168 institutions reported shares at the end of Q3 2026; 45 opened a position, 31 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Adams Street Partners LLC1.7M$182.2MNo change
Invesco Ltd.1.4M$147.3M+548K+66%
Baillie Gifford & Co1.1M$115.1M+180K+20%
T. Rowe Price Associates Inc1.0M+36K+3.6%
Vanguard Capital Management LLC1.0M$108.4M+219K+27%
Vanguard Portfolio Management LLC822K$87.5M-19K-2.2%
Bamco Inc744K$79.2M+1,615+0.2%
T. Rowe Price Investment Management, Inc.698K+605K+651%
Millennium Management LLC560K$59.6M+135K+32%
Wasatch Advisors LP507K$54.0M-11K-2.1%

Company events

All 6 company events

In 12 months: 2 director or officer changes, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Jun 2026Signed a major agreementSame filing: took on new debt8-K
16 Jun 2026Signed a major agreementSame filing: took on new debt8-K
4 Mar 2026Director or officer change8-K
9 Dec 2025Director or officer change8-K
17 Oct 2025Registered new securities for sale (S-1)S-1/A
7 Oct 2025Registered new securities for sale (S-1)S-1

79 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 57%, Customer success & support 8%, Research & science 8%, Operations & administration 5%.

PostedJobLocation
21 Nov 2026Bioinformatics Associate, PrenatalOperations & administrationMenlo Park, CA
18 Nov 2026Clinical Laboratory Scientist, PrenatalResearch & scienceUnion City, CA
18 Nov 2026General Supervisor, PrenatalOperations & administrationUnion City, CA
12 Nov 2026Prenatal Account ExecutiveSales & business developmentSouth Kansas City, MO
11 Nov 2026LIMS Associate, OncologySoftware engineeringMenlo Park, CA
11 Nov 2026Oncology Regional Sales Manager, Gulf CoastSales & business developmentAlabama, Arkansas, Georgia, Kentucky, Tennessee
11 Nov 2026Senior Accounting Manager (Team Leader)Finance & accountingMenlo Park, CA
10 Nov 2026Vice President of Sales, OncologySales & business developmentUnited States

The 5 newest of 164 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 4 Mar 2026Filings record

    Director or officer change

  2. 9 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 9 Dec 2025Filings record

    Director or officer change

  4. 13 Nov 2025Insiders change

    had 6 insiders buy $3.2M of its shares on the open market within 30 days (6 filings).

    Who bought: Bremner Thomas S, Johnson Nancy JoAnn, Rai Akshay, Tsao David and 2 more.

    See the evidence (6 source records)
    Independent buyers
    6
    Purchase filings (Form 4, code P)
    6
    Total bought
    $3.2M
    Window
    14 Oct 2025 to 13 Nov 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  5. 13 Nov 2025Insiders record

    ten Bosch John Roderick (See Remarks) bought 800 shares of BLLN ($48,000) (dated 12 Nov 2025)

  6. 13 Nov 2025Insiders record

    Lynch Thomas P. (See Remarks) bought 100 shares of BLLN ($6,000) (dated 12 Nov 2025)

  7. 13 Nov 2025Insiders record

    Tsao David (Chief Technology Officer) bought 1,000 shares of BLLN ($60,000) (dated 12 Nov 2025)

  8. 13 Nov 2025Insiders record

    Rai Akshay (director) bought 2,500 shares of BLLN ($150,000) (dated 12 Nov 2025)

  9. 13 Nov 2025Insiders record

    Johnson Nancy JoAnn (See Remarks) bought 6,900 shares of BLLN ($414,000) (dated 12 Nov 2025)

  10. 11 Nov 2025Insiders record

    Bremner Thomas S (director) bought 41,666 shares of BLLN ($2.5M) (dated 10 Nov 2025)

  11. 17 Oct 2025Filings record

    Registered new securities for sale (S-1)

  12. 7 Oct 2025Filings record

    Registered new securities for sale (S-1)

Not listed: 52 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002070849
Ticker
BLLN
Domain
billiontoone.com
Employer name
BillionToOne, Inc. (1 unverified)
Hq location
CA|MENLO PARK| (1 unverified)
Name
BillionToOne, Inc.
Uei
KDU8W267SFM8
Wikidata
Q133812186
  • DOL H-1B labor condition applications and PERM certifications110 data points24 Aug 2020 to 14 Sep 2026
  • SEC Form 13F institutional holdings36 data points31 Dec 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)18 records7 Oct 2025 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)161 data points31 Dec 2022 to 30 Sep 2026
  • SEC Form 4 insider transactions44 records, 112 data points10 Nov 2025 to 4 Nov 2026
  • FINRA short interest (twice monthly)71 data points14 Nov 2025 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)524 data points6 Nov 2025 to 20 Nov 2026
  • USASpending.gov federal awards9 data points17 Sep 2018 to 20 Feb 2020